S

Seagen Inc
F:SGT

Watchlist Manager
Seagen Inc
F:SGT
Watchlist
Price: 208.6 EUR Market Closed
Market Cap: 39.4B EUR
Have any thoughts about
Seagen Inc?
Write Note

Relative Value

The Relative Value of one SGT stock under the Base Case scenario is 256.9 EUR. Compared to the current market price of 208.6 EUR, Seagen Inc is Undervalued by 19%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SGT Relative Value
Base Case
256.9 EUR
Undervaluation 19%
Relative Value
Price
S
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
49
vs Industry
Median 3Y
17.7
Median 5Y
17.9
Industry
7.7
Forward
16.4
vs History
vs Industry
Median 3Y
-53.7
Median 5Y
-53.3
Industry
22.7
Forward
-51.4
vs History
vs Industry
Median 3Y
-74
Median 5Y
-74
Industry
21.6
vs History
vs Industry
Median 3Y
-57
Median 5Y
-57
Industry
25.2
vs History
17
vs Industry
Median 3Y
13.7
Median 5Y
11.3
Industry
2.5
vs History
42
vs Industry
Median 3Y
16.8
Median 5Y
16.9
Industry
7.7
Forward
16
vs History
28
vs Industry
Median 3Y
21.6
Median 5Y
21
Industry
9
vs History
vs Industry
Median 3Y
-58.2
Median 5Y
-57.2
Industry
4.2
Forward
-51.5
vs History
vs Industry
Median 3Y
-51.6
Median 5Y
-51.6
Industry
4.1
Forward
-47.7
vs History
vs Industry
Median 3Y
-71.7
Median 5Y
-71.7
Industry
5.7
vs History
vs Industry
Median 3Y
-55.3
Median 5Y
-55.3
Industry
3.6
vs History
47
vs Industry
Median 3Y
18.3
Median 5Y
18.4
Industry
4.6

Multiples Across Competitors

SGT Competitors Multiples
Seagen Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Seagen Inc
F:SGT
39.3B EUR 17.9 -54.9 -59 -53.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 888 840.5 -180 080 -218 674.5 -216 179.2
US
Abbvie Inc
NYSE:ABBV
314.4B USD 5.7 61.9 15.4 23.7
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117B USD 11 -243 24.2 25.5
US
Gilead Sciences Inc
NASDAQ:GILD
112.5B USD 4 892.3 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 859.4 -474.5 -516.7 -502.9
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.3B USD 6 17.7 16.1 17.9
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.6 -130.6 -105.1 -76.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
31.8B USD 15.2 -95.6 -227.4 -159.8
P/E Multiple
Earnings Growth
US
S
Seagen Inc
F:SGT
Average P/E: 208.4
Negative Multiple: -54.9
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 080 N/A
US
Abbvie Inc
NYSE:ABBV
61.9
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -243
42%
US
Gilead Sciences Inc
NASDAQ:GILD
892.3
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -474.5 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
43%
NL
argenx SE
XBRU:ARGX
Negative Multiple: -130.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -95.6 N/A
EV/EBITDA Multiple
EBITDA Growth
US
S
Seagen Inc
F:SGT
Average EV/EBITDA: 17.2
Negative Multiple: -59
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -218 674.5 N/A
US
Abbvie Inc
NYSE:ABBV
15.4
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -516.7 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
46%
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -227.4 N/A
EV/EBIT Multiple
EBIT Growth
US
S
Seagen Inc
F:SGT
Average EV/EBIT: 22.6
Negative Multiple: -53.2
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 179.2 N/A
US
Abbvie Inc
NYSE:ABBV
23.7
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -502.9 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
54%
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -159.8 N/A

See Also

Discover More
Back to Top